{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:54:29Z","timestamp":1786496069743,"version":"build-2736575974"},"reference-count":11,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Grant-in-Aid for Scientific Research","award":["19K08082"],"award-info":[{"award-number":["19K08082"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neuropsychopharm Rep"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>This systematic review and random\u2010effect model, network meta\u2010analysis of the phase 3 trials in Japan assessed the efficacy and safety profile of lurasidone compared with olanzapine and quetiapine extended\u2010release (QUE\u2010XR) for the treatment of bipolar depression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study included double\u2010blind, randomized, placebo\u2010controlled, phase 3 trials in Japan that included patients with bipolar depression. Outcomes included response rate (primary), remission rate (secondary), improvement of Montgomery\u2010\u00c5sberg Depression Rating Scale (MADRS) total score, discontinuation rates, and incidence of individual adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Three studies were included (n\u00a0=\u00a01223). Lurasidone and olanzapine but not QUE\u2010XR were superior to placebo in response rate [risk ratio (95% credible interval): lurasidone\u00a0=\u00a00.78 (0.66, 0.92); olanzapine\u00a0=\u00a00.84 (0.71, 0.99); QUE\u2010XR\u00a0=\u00a00.87 (0.73, 1.03)]. Lurasidone, olanzapine and QUE\u2010XR were superior to placebo in remission rate [lurasidone\u00a0=\u00a00.90 (0.83, 0.98); olanzapine\u00a0=\u00a00.87 (0.77, 0.99); QUE\u2010XR\u00a0=\u00a00.84 (0.73, 0.98)] and the improvement of MADRS total score. There were not differences in discontinuation rates between each antipsychotic and placebo. Compared with placebo, lurasidone was higher incidence of akathisia, and increased body weight and blood prolactin level; olanzapine was higher incidence of somnolence and \u22657% weight gain, and increased body weight, blood total cholesterol level, blood LDL cholesterol level, and blood triglyceride levels; QUE\u2010XR was higher incidence of extrapyramidal symptoms, akathisia, somnolence, dry mouth, constipation and \u22657% weight gain, and increased body weight, blood total cholesterol level, blood LDL cholesterol level, and blood triglyceride levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our results suggested although the efficacy of three SGAs was similar, there were the differences in the safety profile among the SGAs.<\/jats:p><\/jats:sec>","DOI":"10.1002\/npr2.12137","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T08:00:17Z","timestamp":1600070417000},"page":"417-422","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Lurasidone, olanzapine, and quetiapine extended\u2010release for bipolar depression: A systematic review and network meta\u2010analysis of phase 3 trials in Japan"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9237-2236","authenticated-orcid":false,"given":"Taro","family":"Kishi","sequence":"first","affiliation":[{"name":"Department of Psychiatry Fujita Health University School of Medicine Toyoake Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiji","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of Occupational and Environmental Health Kitakyushu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Sakuma","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Fujita Health University School of Medicine Toyoake Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Okuya","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Fujita Health University School of Medicine Toyoake Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Fujita Health University School of Medicine Toyoake Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,9,9]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2010.101"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12609"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.112.108357"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-018-4977-6"},{"key":"e_1_2_13_6_1","unstructured":"NCT01986101.A Phase III Study of SM\u201013496 in Patients With Bipolar I Depression.https:\/\/clinicaltrialsgov\/ct2\/show\/results\/NCT01986101?view=results(accessed May 22 2020)"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"e_1_2_13_9_1","unstructured":"HigginsJ ThomasJ ChandlerJ CumpstonM LiT PageM et al.Cochrane Handbook for Systematic Reviews of Interventions version 6.0.2019.www.trainingcochraneorg\/handbook(accessed May 22 2020)"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"e_1_2_13_11_1","unstructured":"R\u00fcckerG SchwarzerG KrahnU K\u00f6nigJ.netmeta: Network Meta\u2010Analysis using Frequentist Methods (R package version 0.9\u20105).2017.https:\/\/CRANR\u2010projectorg\/package=netmeta(accessed March 14 2020)"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099682"}],"container-title":["Neuropsychopharmacology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnpr2.12137","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.12137","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/npr2.12137","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.12137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T21:49:08Z","timestamp":1693604948000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/npr2.12137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,9]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1002\/npr2.12137"],"URL":"https:\/\/doi.org\/10.1002\/npr2.12137","archive":["Portico"],"relation":{},"ISSN":["2574-173X","2574-173X"],"issn-type":[{"value":"2574-173X","type":"print"},{"value":"2574-173X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,9]]},"assertion":[{"value":"2020-06-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}